Rosen Law Firm urges investors in Skye Bioscience to act before January 16, 2026 deadline

Rosen Law Firm — a global investor‑rights law firm — is calling on anyone who bought shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025 to consider joining a class‑action lawsuit. If you bought SKYE during that “Class Period,” you may be eligible for compensation — without paying any out‑of‑pocket costs — under a contingency‑fee arrangement. To participate, investors must file paperwork or move to serve as lead plaintiff by January 16, 2026. Contact can be made via a submission form on the Rosen website, by phone (toll‑free 866‑767‑3653) or by email. According to the lawsuit, Skye’s prior statements about its drug candidate nimacimab — including claims about its effectiveness and promising clinical, regulatory and commercial prospects — were allegedly false or misleading. The complaint argues that Skye overstated nimacimab’s potential, and when the truth emerged, investors suffered losses. Rosen emphasizes choosing experienced counsel, noting that many firms behind similar notices lack the track record or resources to lead securities class‑action litigation. The firm points to its record of significant settlements and peer recognition as a reason to trust its representation. #SkyeBioscience #SecuritiesClassAction #InvestorAlert #RosenLawFirm #SlimScan #GrowthStocks #CANSLIM